ストックスクリーナーアプリを入手
4.30
0.92%
-0.04
アフターアワーズ：
4.26
-0.04
-0.93%
C 4 Therapeutics Inc (CCCC) 最新ニュース
Price to book forward of C4 Therapeutics, Inc. – NASDAQ:CCCC - TradingView
Price to earnings forward of C4 Therapeutics, Inc. – NASDAQ:CCCC - TradingView
Price to sales forward of C4 Therapeutics, Inc. – NASDAQ:CCCC - TradingView
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
CCCC Stock Climbs As C4 Therapeutics Posts Strong Phase 1 Myeloma Data - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
[144] Candel Therapeutics, Inc. SEC Filing - Stock Titan
Director at vTv Therapeutics (VTVT) awarded 6,000 stock options grant - Stock Titan
C4 Therapeutics, Inc.(NasdaqGS: CCCC) added to Russell 2000 Index - marketscreener.com
C4 Therapeutics, Inc.(NasdaqGS: CCCC) added to Russell 2000 Value Benchmark - marketscreener.com
C4 Therapeutics, Inc.(NasdaqGS: CCCC) added to Russell 2500 Value Benchmark - marketscreener.com
Are medical stocks lagging C4 Therapeutics (CCCC) this year? - MSN
Form 4 C4 Therapeutics Inc For: 26 June By Investing.com - Investing.com Nigeria
C4 Therapeutics (NASDAQ: CCCC) director receives 62,000 stock options at $4.25 - Stock Titan
Director Steven Hoerter gets 62,000 C4 Therapeutics (CCCC) options at $4.25 - Stock Titan
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L. - Moomoo
Contineum Therapeutics (CTNM) awards director 19,000-share stock option grant - Stock Titan
Contineum Therapeutics (CTNM) elects Class II directors, ratifies Ernst & Young as 2026 auditor - Stock Titan
C4 Therapeutics (NASDAQ: CCCC) director receives grant of 62,000 stock options - Stock Titan
[Form 4] C4 Therapeutics, Inc. Insider Trading Activity - Stock Titan
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Anderson Kenneth Carl - Moomoo
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Director at C4 Therapeutics (CCCC) granted 62,000 stock options at $4.25 - Stock Titan
C4 Therapeutics (CCCC) director awarded 62,000 stock options at $4.25 strike - Stock Titan
C4 Therapeutics (CCCC) director receives 62,000-share stock option award - Stock Titan
C4 Therapeutics (CCCC) director receives grant of 62,000 stock options - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes - Stock Titan
CCCC Forecast — Price Target — Prediction for 2027 - TradingView
Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares - Stock Titan
C4 Therapeutics, Inc. Actuals & Estimates (NASDAQ:CCCC) - TradingView
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Morningstar
EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC) - Stock Titan
C4 Therapeutics Inc (CCCC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
C4 Therapeutics Shareholders Back Directors, Pay and Auditors - TipRanks
Candel Therapeutics (CADL) director granted 32,000 stock options - Stock Titan
Candel Therapeutics (CADL) grants director 32,000 stock options at $9.08 - Stock Titan
C4 Therapeutics (NASDAQ: CCCC) investors approve directors, pay and stock plan change - Stock Titan
C4 Therapeutics (CCCC) AGM 2026 Summary - Quartr
C4 Therapeutics Inc (CCCC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Andrea Martin drives innovative science and mentorship at C4 Therapeutics, Inc. - Traders Union
Atrium Therapeutics awards stock grants to 8 new hires - Stock Titan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Inc (CCCC) Valuation: PE, PB & Fair Value Analysis - TradingKey
C4 Therapeutics Inc (CCCC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including CemsidomideSlideshow (NASDAQ:CCCC) 2026-06-20 - Seeking Alpha
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance
C4 Therapeutics, Inc Educational KOL Webinar Transcript - GuruFocus
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics Inc (CCCC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
C4 Therapeutics Inc (CCCC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
C4 Therapeutics Inc (CCCC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
C4 Therapeutics Inc (CCCC) Institutional Confidence - TradingKey
C4 Therapeutics Inc (CCCC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
3.86%
大文字化:
|
ボリューム (24 時間):